School of Medicine
Showing 241-250 of 729 Results
-
Benjamin Davies Horne
Adjunct Clinical Associate Professor, Medicine - Cardiovascular Medicine
BioDr. Benjamin Horne is an Adjunct Clinical Associate Professor who is based at the Intermountain Medical Center Heart Institute in Salt Lake City, UT, where he serves as the Director of Cardiovascular and Genetic Epidemiology. His doctoral training (PhD) in genetic epidemiology was completed at the University of Utah and he holds masters degrees in public health and in biostatistics. Dr. Horne is a fellow of the American Heart Association, a fellow of the American College of Cardiology, and a member of the American Society of Human Genetics. Dr. Horne’s research focuses on population health and precision medicine, including evaluating the genetic epidemiology of heart diseases, developing and implementing clinical decision tools for personalizing medical care, discovering the human health effects of intermittent fasting, and studying the influences of air pollution on major adverse health events.
-
Ngan F. Huang
Associate Professor of Cardiothoracic Surgery (Cardiothoracic Surgery Research) and, by courtesy, of Chemical Engineering
Current Research and Scholarly InterestsDr. Huang's laboratory aims to understand the chemical and mechanical interactions between extracellular matrix (ECM) proteins and pluripotent stem cells that regulate vascular and myogenic differentiation. The fundamental insights of cell-matrix interactions are applied towards stem cell-based therapies with respect to improving cell survival and regenerative capacity, as well as engineered vascularized tissues for therapeutic transplantation.
-
Gentaro Ikeda
Instructor, Medicine - Cardiovascular Medicine
BioDr. Ikeda is a physician-scientist who develops innovative diagnostic and therapeutic modalities for patients with cardiovascular disease. Based on his clinical experience as a cardiologist, he has become aware of major clinical shortcomings, specifically in the current pharmaceutical therapies for myocardial infarction (MI) and chronic heart failure (HF). Some evidence-based drug therapies, including β-blockers, ivabradine, and renin-angiotensin-aldosterone antagonists are difficult to apply to critical patients due to adverse side effects. Drugs that have shown efficacy in basic animal experiments have failed to show significant benefits in clinical trials. To address these problems, he moved to academia to conduct translational research. During his graduate training in the Egashira Lab, he focused on drug delivery systems (DDS) that target mitochondria in animal models of MI. He obtained advanced skills in molecular biology, mitochondrial bioenergetics, and animal surgery. He realized the importance of translational research and the great potential of DDS to overcome many clinical problems. He developed nanoparticle-mediated DDS containing cyclosporine for the treatment of patients with MI. He published a first-author paper and received academic awards for his novel science. Since becoming a postdoctoral fellow in the Yang Lab, he has continued to build upon his previous training in translational research. He is currently developing an innovative therapy, namely, extracellular vesicles-mediated mitochondrial transfer for mitochondria-related diseases such as heart failure and mitochondrial disease.